Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Vertex Pharmaceuticals fell $0.91 (-1.1%) to $79.52 on light volume. Throughout the day, 1,590,548 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,509,800 shares. The stock ranged in price between $78.82-$81.88 after having opened the day at $80.60 as compared to the previous trading day's close of $80.43. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 39.8%, Achillion Pharmaceuticals ( ACHN), down 25.1%, Prima Biomed ( PBMD), down 11.7% and Oramed Pharmaceuticals ( ORMP), down 11.1%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.7 billion and is part of the health care sector. Shares are up 91.1% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the positive front, Ambit Biosciences ( AMBI), up 18.2%, Aoxing Pharmaceutical Company ( AXN), up 13.9%, Celldex Therapeutics ( CLDX), up 12.3% and Puma Biotechnology ( PBYI), up 12.3% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns